Search References Drug Actions/Targets About Access data Feedback
Sign In
mitontu@gmail.com
2021 MitoTox | (CC BY-NC 4.0)
Drug

D0485 | aripiprazole

Molecular Formula C23H27Cl2N3O2
Molecular Weight 448.4
Structure
State solid
Clearance 0.8mL/min/kg[A31184]. Other studies have reported a clearance rate of 3297±1042mL/hr[A177904].
Volume of distribution 404L or 4.9L/kg[Label,A31184].
Route of elimination 25% of a given dose will be eliminated in urine and 55% in the feces[Label,A177910]. <1% of a dose is eliminated in the urine as unmetabolized aripiprazole and approximately 18% of a dose will be eliminated in the feces unmetabolized[Label,A177910].
Protein binding >99%[Label].
Half life The half life of aripiprazole is 75 hours while the half life of the active metabolite is 94 hours[Label]. For populations that are poor CYP2D6 metabolizers, the half life of aripiprazole is 146 hours and these patients should be treated with half the normal dose[Label]. Other studies have reported a half life of 61.03±19.59 hours for aripiprazole and 279±299 hours for the active metabolite[A177904].
Absorption Aripiprazole tablets are 87% bioavailable and reach peak plasma concentrations in 3 to 5 hours[Label]. These tablets can be taken with or without food, but a high fat meal can delay the time to max concentration by 3 hours and up to 12 hours for the active metabolite[Label].

N

N05AX12 Aripiprazole


[N05AX] Other antipsychotics


[N05A] ANTIPSYCHOTICS


[N05] PSYCHOLEPTICS


[N] Nervous system

Toxicity Dose Time Species Model Method Action Positive criterion Reference
ELECTRON TRANSPORT CHAIN rat isolated liver mitochondria measurements of mitochondrial respiration; RST inhibition assay, RST uncoupling assay; IC 50ratio of glucose/galactose assay decrease 53

Pictogram Signal Statements Precautionary Statement Codes
Danger

Aggregated GHS information provided by 174 companies from 17 notifications to the ECHA C&L Inventory.


H301 (90.8%): Toxic if swallowed [Danger Acute toxicity, oral]


Information may vary between notifications depending on impurities, additives, and other factors. The percentage value in parenthesis indicates the notified classification ratio from companies that provide hazard codes. Only hazard codes with percentage values above 10% are shown.


 P264, P270, P301+P310, P321, P330, P405, and P501; (The corresponding statement to each P-code can be found at the GHS Classification page.)
Danger

H226: Flammable liquid and vapor [Warning Flammable liquids]


H290: May be corrosive to metals [Warning Corrosive to Metals]


H301: Toxic if swallowed [Danger Acute toxicity, oral]


H311: Toxic in contact with skin [Danger Acute toxicity, dermal]


H315: Causes skin irritation [Warning Skin corrosion/irritation]


H319: Causes serious eye irritation [Warning Serious eye damage/eye irritation]


H331: Toxic if inhaled [Danger Acute toxicity, inhalation]


H370: Causes damage to organs [Danger Specific target organ toxicity, single exposure]


 P210, P233, P234, P240, P241, P242, P243, P260, P261, P264, P270, P271, P280, P301+P310, P302+P352, P303+P361+P353, P304+P340, P305+P351+P338, P307+P311, P311, P312, P321, P322, P330, P332+P313, P337+P313, P361, P362, P363, P370+P378, P390, P403+P233, P403+P235, P404, P405, and P501; (The corresponding statement to each P-code can be found at the GHS Classification page.)


  • 129722-12-9 2(1H)-Quinolinone, 7-(4-(4-(2,3-dichlorophenyl)-1-piperazinyl)butoxy)-3,4-dihydro- 2(1H)-Quinolinone, 7-[4-[4-(2,3-dichlorophenyl)-1-piperazinyl]butoxy]-3,4-dihydro-
    24-29-3 4811-EP2269990A1 4811-EP2272841A1
    4811-EP2298731A1 4811-EP2298776A1 4811-EP2301936A1
    7-(4-(4-(2,3-DICHLOROPHENYL)PIPERAZIN-1-YL)BUTOXY)-3,4-DIHYDROQUINOLIN-2(1H)-ONE 7-(4-(4-(2,3-Dichlorophenyl)-1-piperazinyl)butoxy)-3,4-dihydro-2(1H)-quinolinone 7-(4-(4-(2,3-Dichlorophenyl)-1-piperazinyl)butoxy)-3,4-dihydrocarbostyril
    7-(4-(4-(2,3-Dichlorophenyl)-1-piperazinyl)butyloxy)-3,4-dihydro-2(1H)-quinolinone 7-(4-(4-(2,3-dichlorophenyl)-1-piperazinyl)butoxy)-3,4-dihydrocarbostyril 7-(4-[4-(2,3-dichlorophenyl)-1-piperazinyl]butoxy)-3,4-dihydrocarbostyril
    7-(4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butoxy)-3,4-dihydroquinolin-2(1H)-one 7-[4-(4-(2,3-Dichlorophenyl)piperazin-1-yl)butoxy]-3,4-dihydro-2(1H)-quinolinone 7-[4-[4-(2,3-Dichlorophenyl)-1-Piperazinyl]Butoxy]3,4-Dihydro-2(1H)-Quinolinone
    7-[4-[4-(2,3-Dichlorophenyl)-1-piperazinyl]butoxy]-3,4-dihydro-2(1H)-quinolinone 7-[4-[4-(2,3-Dichlorophenyl)-1-piperazinyl]butoxy]-3,4-dihydrocarbostyril 7-[4-[4-(2,3-Dichlorophenyl)-1-piperazinyl]butoxy]-3,4-dihydrocarbostyril
    7-[4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butoxy]-3,4-dihydro-1H-quinolin-2-one 7-[4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butoxy]-3,4-dihydro-quinolin-2(1H)-one 7-[4-[4-[2,3-bis(chloranyl)phenyl]piperazin-1-yl]butoxy]-3,4-dihydro-1H-quinolin-2-one
    7-{4-[-4-(2,3-dichlorophenyl)-1-piperazinyl]butoxy}-3,4-dihydrocarbostyril 7-{4-[4-(2,3-Dichloro-phenyl)-piperazin-1-yl]-butoxy}-3,4-dihydro-1H-quinolin-2-one 7-{4-[4-(2,3-Dichlorophenyl)piperazin-1-yl]butoxy}-3,4-dihydroquinolin-2(1H)-one
    7-{4-[4-(2,3-dichlorophenyl)-1-piperazinyl]butoxy}-3, 4-dihydrocarbostyril 7-{4-[4-(2,3-dichlorophenyl)-1-piperazinyl]butoxy}-3,4-dihydrocarbostyril 7-{4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butoxy}-1,2,3,4-tetrahydroquinolin-2-one
    7-{4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butoxy}-3,4-dihydroquinolin-2(1H)-one 7-{4-[4-(2,3-dichlorophenyl)piperazino]butoxy}-3,4-dihydro-2(1H)-quinolinone 722A129
    82VFR53I78 9SC A11801
    A19454 AB0008434 AB00639935-09
    AB00639935_10 AB00639935_11 AB07660
    AB1006698 AC-1554 ACMC-20emtv
    ACT03221 AK-46736 AKOS005558247
    AM20090766 AOB5922 Abilify
    Abilify (TN) Abilify Digital Abilify Discmelt
    Abilify Maintena Abilify Maintena Kit Abilify MyCite
    Abilify OD Abilitat Aripiprazole
    Aripiprazole (Abilify) Aripiprazole (JAN/USAN/INN) Aripiprazole 1.0 mg/ml in Acetonitrile
    Aripiprazole D8 Aripiprazole Depot Aripiprazole [USAN:INN:BAN]
    Aripiprazole [USAN] Aripiprazole solution, 1.0 mg/mL (50:50 Methanol/Water with 1% 1N HCl), ampule of 1 mL, certified reference material Aripiprazole solution, 1.0 mg/mL in acetonitrile, ampule of 1 mL, certified reference material;
    Aripiprex Aripirazole Aristada (aripiprazole lauroxil)
    BBL029082 BCP04902 BCP9000317
    BDBM50130293 BMS-337039 BR-46736
    BRD-K70358946-001-06-6 C12564 C23H27Cl2N3O2
    CA0141 CAS-129722-12-9 CCG-100891
    CEUORZQYGODEFX-UHFFFAOYSA-N CHEBI:31236 CHEMBL1112
    CPD000466383 CS-0766 CTK0H5518
    D01164 DB01238 DL-178
    DSSTox_CID_26083 DSSTox_GSID_46083 DSSTox_RID_81324
    DTXSID3046083 Discmelt EBD20357
    FT-0082572 FT-0600352 GTPL34
    HMS2051I18 HMS2089M20 HMS2093F22
    HMS2230M18 HMS3373D04 HMS3393I18
    HMS3657K13 HMS3715J07 HMS3744A13
    HSDB 7320 HY-14546 J-005707
    J10066 KS-00000XK7 KS-1030
    L001339 LS-142666 MCULE-4329329262
    MFCD00892072 MLS000759517 MLS001165779
    MLS001195621 MLS001424078 MLS006011892
    NC00141 NCGC00159510-02 NCGC00159510-03
    NCGC00159510-04 NCGC00159510-05 NSC-759266
    NSC759266 OPC 31 OPC-14597
    OPC-31 Opc 14597 Pharmakon1600-01505851
    PubChem18143 Q411188 RTR-004086
    S-4507 SAM001246750 SBI-0206870.P001
    SC-16317 SCHEMBL12961254 SCHEMBL5335696
    SCHEMBL8255 SMR000466383 SR-01000759353
    SR-01000759353-4 SR-01000759353-6 ST2412627
    STK625160 SW197521-3 SY053146
    Tox21_111728 Tox21_111728_1 UNII-82VFR53I78
    Z1541632800 ZINC1851149 aripiprazol
    aripiprazole aripiprazole-abilify aripiprazolum
    s1975

    DrugBank Name aripiprazole
    DrugBank DB01238
    CAS Number 1026778-41-5, 1089115-04-7, 1089115-06-9, 129722-12-9, 24-29-3
    PubChem Compound 60795
    KEGG Compound ID C12564
    KEGG Drug D01164
    ChEBI 31236
    PharmGKB PA10026